Dr. Reddy's Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the US Market
25 January 2019 - - Indian drugmaker Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched of Propofol Injectable Emulsion, USP, a therapeutic equivalent generic version of Diprivan (propofol) Injectable Emulsion, USP, approved by the US Food and Drug Administration (USFDA), the company said.

Propofol, marketed as Diprivan among other names, is a short-acting medication that results in a decreased level of consciousness. The Missouri Supreme Court in the USA decided to allow the use of propofol to execute prisoners condemned to death. 

Dr. Reddy's said it neither condones nor supports the off-label use or misuse of its drugs. In the strongest possible terms, Dr. Reddy's objects to the use of any of its products to facilitate or otherwise aid lethal injections.

Consistent with this position, Dr. Reddy's uses distribution controls to market Propofol Injectable Emulsion, USP. Dr. Reddy's said it will not accept orders from correctional facilities and prison systems whose intended use of the product is to aid in lethal injection. We require the same commitment from our wholesalers and distributors.

The Diprivan brand and generic had US sales of approximately USD 310m MAT for the most recent twelve months ending in November 2018 according to IMS Health.

Dr. Reddy's Propofol Injectable Emulsion, USP is available in 10 mg/mL vials for Single Patient Use Only.
Please for Full Prescribing Information.

Diprivan is a trademark of Fresenius Kabi USA, LLC.

Dr. Reddy's Laboratories is an integrated pharmaceutical company whose major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's major markets include USA, India, Russia and CIS countries, and Europe.